These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 35855239)

  • 1. Ethnical Disparities in Response to Edaravone in Patients With Amyotrophic Lateral Sclerosis.
    Jayasinghe M; Jena R; Singhal M; Jain S; Karnakoti S; Silva MS; Kayani AMA
    Cureus; 2022 Jun; 14(6):e25960. PubMed ID: 35855239
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Edaravone: a new hope for deadly amyotrophic lateral sclerosis.
    Bhandari R; Kuhad A; Kuhad A
    Drugs Today (Barc); 2018 Jun; 54(6):349-360. PubMed ID: 29998226
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Riluzole and Edavarone: The Hope Against Amyotrophic Lateral Sclerosis.
    Rokade AV; Yelne P; Giri A
    Cureus; 2022 Oct; 14(10):e30035. PubMed ID: 36381733
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Riluzole and edaravone: A tale of two amyotrophic lateral sclerosis drugs.
    Jaiswal MK
    Med Res Rev; 2019 Mar; 39(2):733-748. PubMed ID: 30101496
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic news in ALS.
    Corcia P; Beltran S; Bakkouche SE; Couratier P
    Rev Neurol (Paris); 2021 May; 177(5):544-549. PubMed ID: 33781562
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estimating Amyotrophic Lateral Sclerosis and Motor Neuron Disease Prevalence in Portugal Using a Pharmaco-Epidemiological Approach and a Bayesian Multiparameter Evidence Synthesis Model.
    Conde B; Winck JC; Azevedo LF
    Neuroepidemiology; 2019; 53(1-2):73-83. PubMed ID: 31117082
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Magnetic resonance metrics to evaluate the effect of therapy in amyotrophic lateral sclerosis: the experience with edaravone.
    Distaso E; Milella G; Mezzapesa DM; Introna A; D'Errico E; Fraddosio A; Zoccolella S; Dicuonzo F; Simone IL
    J Neurol; 2021 Sep; 268(9):3307-3315. PubMed ID: 33655342
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of Plant-Derived Compounds on Amyotrophic Lateral Sclerosis.
    de Oliveira LMG; Carreira RB; de Oliveira JVR; do Nascimento RP; Dos Santos Souza C; Trias E; da Silva VDA; Costa SL
    Neurotox Res; 2023 Jun; 41(3):288-309. PubMed ID: 36800114
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Edaravone May Prevent Ferroptosis in ALS.
    Spasić S; Nikolić-Kokić A; Miletić S; Oreščanin-Dušić Z; Spasić MB; Blagojević D; Stević Z
    Curr Drug Targets; 2020; 21(8):776-780. PubMed ID: 32077821
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A perspective on therapies for amyotrophic lateral sclerosis: can disease progression be curbed?
    Xu X; Shen D; Gao Y; Zhou Q; Ni Y; Meng H; Shi H; Le W; Chen S; Chen S
    Transl Neurodegener; 2021 Aug; 10(1):29. PubMed ID: 34372914
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Two Decades-Long Journey from Riluzole to Edaravone: Revisiting the Clinical Pharmacokinetics of the Only Two Amyotrophic Lateral Sclerosis Therapeutics.
    Dash RP; Babu RJ; Srinivas NR
    Clin Pharmacokinet; 2018 Nov; 57(11):1385-1398. PubMed ID: 29682695
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Investigating Edaravone Use for Management of Amyotrophic Lateral Sclerosis (ALS): A Narrative Review.
    Neupane P; Thada PK; Singh P; Faisal AR; Rai N; Poudel P; Waleed MS; Quinonez J; Ruxmohan S; Jain E
    Cureus; 2023 Jan; 15(1):e33746. PubMed ID: 36788871
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current State and Future Directions in the Therapy of ALS.
    Tzeplaeff L; Wilfling S; Requardt MV; Herdick M
    Cells; 2023 May; 12(11):. PubMed ID: 37296644
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Edaravone for the treatment of amyotrophic lateral sclerosis.
    Yoshino H
    Expert Rev Neurother; 2019 Mar; 19(3):185-193. PubMed ID: 30810406
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Isolated pulmonary recovery in a veteran with late stage bulbar ALS following edaravone treatment and cessation.
    Verma S; Lim J; Buscemi-Kimmins T; Brose SW
    J Spinal Cord Med; 2022 Jul; 45(4):638-642. PubMed ID: 34982644
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic opportunities and challenges of induced pluripotent stem cells-derived motor neurons for treatment of amyotrophic lateral sclerosis and motor neuron disease.
    Jaiswal MK
    Neural Regen Res; 2017 May; 12(5):723-736. PubMed ID: 28616022
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Using an expanded algorithm to estimate prevalence of amyotrophic lateral sclerosis in U.S. and UK.
    Abbasi A; Fryk H; Rudnik J; White R; Vanderkelen M; Scowcroft A; Bonar K
    Neurol Sci; 2024 May; 45(5):2321-2324. PubMed ID: 38270730
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CNM-Au8: an experimental agent for the treatment of amyotrophic lateral sclerosis (ALS).
    Bireley JD; Morren JA
    Expert Opin Investig Drugs; 2023; 32(8):677-683. PubMed ID: 37642362
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Multifaceted Role of GPCRs in Amyotrophic Lateral Sclerosis: A New Therapeutic Perspective?
    Bassani D; Pavan M; Federico S; Spalluto G; Sturlese M; Moro S
    Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35562894
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral Edaravone - Introducing a Flexible Treatment Option for Amyotrophic Lateral Sclerosis.
    Pattee GL; Genge A; Couratier P; Lunetta C; Sobue G; Aoki M; Yoshino H; Jackson CE; Wymer J; Salah A; Nelson S
    Expert Rev Neurother; 2023; 23(10):859-866. PubMed ID: 37646130
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.